Igor Puzanov

Igor Puzanov

UNVERIFIED PROFILE

Are you Igor Puzanov?   Register this Author

Register author
Igor Puzanov

Igor Puzanov

Publications by authors named "Igor Puzanov"

Are you Igor Puzanov?   Register this Author

100Publications

18744Reads

38Profile Views

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.

J Immunother Cancer 2019 Aug 15;7(1):221. Epub 2019 Aug 15.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0683-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696687PMC
August 2019

The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugs.

JAMA Dermatol 2019 Jul;155(7):862-863

Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2019.0594DOI Listing
July 2019

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

J Transl Med 2019 May 10;17(1):148. Epub 2019 May 10.

Clinical Trials Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-019-1892-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509811PMC
May 2019

BRAF Inhibition in BRAF-Mutant Gliomas: Results From the VE-BASKET Study.

J Clin Oncol 2018 Oct 23:JCO2018789990. Epub 2018 Oct 23.

Thomas Kaley, Lisa M. DeAngelis, Jose Baselga, and David M. Hyman, Memorial Sloan Kettering Cancer Center; Thomas Kaley, Lisa M. DeAngelis, Jose Baselga, and David M. Hyman, Weill Cornell Medical College, New York; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Mehdi Touat and Antoine Hollebecque, Institut Gustave Roussy, Villejuif; Franck Bielle, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris; Florence Joly, Centre François Baclesse, Caen; Jean-Yves Blay, Centre Léon Bérard, Lyon, France; Vivek Subbiah, MD Anderson Cancer Center, Houston, TX; Jordi Rodon, Vall d'Hebron University Hospital, Barcelona, Spain; A. Craig Lockhart, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Vicki Keedy, Vanderbilt University Medical Center, Nashville, TN; Ralf-Dieter Hofheinz, Universitätsmedizin Mannheim, Mannheim; Jurgen Wolf, Universitätsklinikum Köln, Cologne, Germany; Ian Chau, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Noopur S. Raje, Massachusetts General Hospital, Boston, MA; Martina Makrutzki, F Hoffmann-La Roche, Basel, Switzerland; Todd Riehl, Genentech, South San Francisco, CA; and Bethany Pitcher, F Hoffmann-La Roche, Mississauga, Ontario, Canada.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.9990
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.9990DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286161PMC
October 2018

Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician.

J Pain Symptom Manage 2018 09 22;56(3):460-472. Epub 2018 May 22.

Palliative Medicine Program, Johns Hopkins Hospital, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08853924183026
Publisher Site
http://dx.doi.org/10.1016/j.jpainsymman.2018.05.015DOI Listing
September 2018

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

N Engl J Med 2018 Aug;379(8):722-730

From the University of Texas M.D. Anderson Cancer Center, Houston (H.A.T.); Moffitt Cancer Center and Research Institute, Tampa, FL (P.A.F., N.I.K.); University of California-San Francisco, San Francisco (A. Algazi), the Angeles Clinic and Research Institute, Los Angeles (O.H.), Stanford University Hospital, Palo Alto (R.P.T.), and the Department of Medical Oncology, City of Hope, Duarte (K.M.) - all in California; Dana-Farber Cancer Institute, Boston (F.S.H., D.A.R.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (S.J.M.); University of Colorado Comprehensive Cancer Center, Aurora (K.L.); University of Michigan, Ann Arbor (C.D.L.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (M.A.P.), Roswell Park Cancer Institute, Buffalo (M.S.E., I.P.), and New York University, Lake Success (A.C.P.) - all in New York; Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); Winship Cancer Institute of Emory University, Atlanta (R.R.K.); University of Pittsburgh Medical Center, Pittsburgh (A.T.); Bristol-Myers Squibb, Princeton, NJ (J.J., A. Avila, S.D.); and Cleveland Clinic-Taussig Cancer Institute, Cleveland (A.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805453DOI Listing
August 2018

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

J Clin Oncol 2018 06 5;36(17):1658-1667. Epub 2017 Oct 5.

Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste Lebbé, Assistance Publique-Hôpital De Paris Dermatology and CIC Hôpital Saint Louis University Paris Diderot Sorbonne, Institut National de la Santé et de la Recherche Médicale U976, Paris, France; Robert H.I. Andtbacka, University of Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.7379
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.7379DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075852PMC
June 2018

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2018 06 14;36(17):1714-1768. Epub 2018 Feb 14.

Julie R. Brahmer, Johns Hopkins Kimmel Cancer Center; Jennifer S. Mammen, Johns Hopkins University, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria; Alexander Spira, Virginia Cancer Specialists and US Oncology Research, Fairfax, VA; Bryan J. Schneider, University of Michigan Health System, Ann Arbor, MI; Michael B. Atkins, Georgetown Lombardi Comprehensive Cancer Center; Cristina A. Reichner, Georgetown University; Laura D. Porter, Colon Cancer Alliance; Washington, DC; Kelly J. Brassil, Aung Naing, Loretta J. Nastoupil, Maria E. Suarez-Almazor, and Yinghong Wang, MD Anderson Cancer Center, Houston, TX; Jeffrey M. Caterino, The Ohio State University Wexner Medical Center, Columbus, OH; Ian Chau, The Royal Marsden Hospital and Institute of Cancer Research, London and Surrey, United Kingdom; Marc S. Ernstoff and Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Bianca D. Santomasso and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center; Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Pamela Ginex, Oncology Nursing Society, Pittsburgh, PA; Jennifer M. Gardner, Seattle Cancer Care Alliance and University of Washington, Seattle, WA; Sigrun Hallmeyer, Oncology Specialists SC, Park Ridge, IL; Jennifer Holter Chakrabarty, University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; David F. McDermott, Beth Israel Deaconess Medical Center; Carole Seigel, Massachusetts General Hospital Cancer Center, Boston, MA; John A. Thompson, Seattle Cancer Care Alliance, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621PMC
June 2018

Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.

J Immunother Cancer 2017 17;5. Epub 2017 Jan 17.

Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232 USA ; Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0206-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240268PMC
April 2018

The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.

J Transl Med 2018 04 17;16(1):101. Epub 2018 Apr 17.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
https://translational-medicine.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s12967-018-1477-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905181PMC
April 2018

Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma.

Circ Heart Fail 2018 03;11(3):e004408

From the Division of Cardiovascular Medicine (A.B.C., J.C.F.) and Division of Oncology (N.A.), Department of Medicine, University of Utah, Salt Lake City; Department of Biostatistics, Epidemiology and Informatics (R.A.H., B.K.), Division of Cardiology (J.A.C., D.H., A.M.S., T.P., V.E., B.K.), Division of Hematology and Oncology (S.K., N.B.H., V.N.), and Division of Nephrology (R.T.), Department of Medicine, and Abramson Cancer Center (S.K., N.B.H., V.N., B.K.), University of Pennsylvania, Philadelphia; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY (I.P.); Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin, Madison (S.E.); Division of Cardiovascular Medicine, Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH (C.E.); Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (M.G.); and Division of Cardiology, Department of Medicine, Washington University in St Louis, MO (D.L.).

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.117
Publisher Site
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.117.004408DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360089PMC
March 2018

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.

J Immunother Cancer 2016 18;4:60. Epub 2016 Oct 18.

Departments of Medicine, Vanderbilt Ingram Cancer Center, 777 PRB, 2220 Pierce Ave., Nashville, TN 37232 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0166-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067899PMC
February 2018

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Melanoma Res 2017 12;27(6):585-590

aDepartment of Internal Medicine, Advocate Medical Group - Oncology North, Park Ridge, Illinois bMelanoma Research Clinic, University of Colorado Cancer Center, Aurora, Colorado cDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia dDepartment of Hematology and Oncology, The University of Arizona Cancer Center, Tucson, Arizona eDepartment of Medicine, Washington University School of Medicine, St Louis, Missouri fDepartment of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee gDepartment of Surgery, Columbia University Medical Center, New York, New York hDepartment of Medical Oncology, Texas Oncology, Dallas, Texas iDepartment of Medicine, Jonsson Comprehensive Cancer Center at University of California jDepartment of Immuno-Oncology, The Angeles Clinic and Research Institute, Los Angeles kDepartment of Oncology, Moores Cancer Center, University of California, San Diego, La Jolla lGenentech Inc., South San Francisco, California mMid Ohio Oncology and Hematology Inc., Columbus, Ohio nDepartment of Melanoma, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC oDepartment of Pathology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania pDepartment of Melanoma, Carol G. Simon Cancer Center, Atlantic Health System, Morristown, New Jersey, USA.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00008390-201712000-0000
Publisher Site
http://dx.doi.org/10.1097/CMR.0000000000000398DOI Listing
December 2017

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

J Clin Oncol 2017 Aug 10;35(22):2535-2541. Epub 2017 May 10.

Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.5952DOI Listing
August 2017

Challenges faced when identifying patients for combination immunotherapy.

Future Oncol 2017 Aug 24;13(18):1607-1618. Epub 2017 Aug 24.

Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0218DOI Listing
August 2017

A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.

J Neurooncol 2017 Jun 9;133(2):435-442. Epub 2017 May 9.

Department of Radiation Oncology, University of Arkansas for Medical Sciences, 4301 W. Markham, Little Rock, AR, 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2455-3DOI Listing
June 2017

mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study.

Onco Targets Ther 2017 17;10:965-971. Epub 2017 Feb 17.

Melanoma Section, Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S120440DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322838PMC
February 2017

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.

J Immunother 2017 01;40(1):31-35

*Vanderbilt University Medical Center, Nashville, TN †Beth Israel Deaconess Medical Center ‡Dana-Farber Cancer Institute §Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/immunotherapy-journal/2017/0100
Web Search
http://dx.doi.org/10.1097/CJI.0000000000000148DOI Listing
January 2017

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

Eur J Cancer 2016 11 2;67:46-54. Epub 2016 Sep 2.

Department of Medicine, Division of Hematology-Oncology, Jonsson Comprehensive Cancer Center (JCCC) at the University of California, Los Angeles (UCLA), 10833 Le Conte Ave, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049163234
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2016.07.018DOI Listing
November 2016

Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

N Engl J Med 2016 Nov;375(18):1749-1755

From the Departments of Medicine (D.B.J., J.M.B., M.H., I.P., M.R.A., T.L.B., J.R.B., D.A.S., E.J.P., M.A.P., D.M.R., J.A.S., J.J.M.), Cancer Biology (J.M.B., J.J.M.), Pathology, Microbiology, and Immunology (M.L.C., L.C.-O., R.D.H.), Biostatistics (Y.X.), Pharmacology (D.M.R.), and Biomedical Informatics (Y.X., D.M.R.), the Cardio-oncology Program (D.A.S., J.J.M.), the Breast Cancer Research Program (J.M.B.), and the Center for Quantitative Sciences (Y.X.), Vanderbilt University Medical Center, Nashville; the Department of Medicine (S.C.) and the Division of Neuroimmunology (S.C., I.J.K.), Beth Israel Deaconess Medical Center, the Departments of Medicine (B.A.O., C.E.S., J.G.S.) and Pathology (A.H.L.), Brigham and Women's Hospital, the Department of Genetics, Harvard Medical School (J.G., C.E.S., J.G.S.) - all in Boston; Howard Hughes Medical Institute, Chevy Chase, MD (C.E.S.); Bristol-Myers Squibb, New York (N.K., G.P., D.S.R., J.S.D.); Neon Therapeutics, Cambridge, MA (R.P.D.); and the Departments of Pathology (J.M.T., R.A.A.), Dermatology (J.M.T.), and Oncology (L.A.D.), Johns Hopkins University, Baltimore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5247797PMC
November 2016

Responses to immune checkpoint inhibitors in nonagenarians.

Oncoimmunology 2016 18;5(11):e1234572. Epub 2016 Oct 18.

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1234572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139628PMC
October 2016

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.

Clin Genitourin Cancer 2016 08 23;14(4):304-313.e6. Epub 2016 Feb 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.02.007DOI Listing
August 2016

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

J Clin Oncol 2016 08 13;34(22):2619-26. Epub 2016 Jun 13.

Igor Puzanov, Vanderbilt University, Nashville, TN; Mohammed M. Milhem, University of Iowa, Iowa City, IA; David Minor, California Pacific Melanoma Center, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; and Ai Li, Lisa Chen, Michael Chastain, Kevin S. Gorski, Abraham Anderson, and Jeffrey Chou, Amgen, Thousand Oaks, CA; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; and Robert H.I. Andtbacka, University of Utah, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1529DOI Listing
August 2016

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.

Expert Rev Anticancer Ther 2015 ;15(12):1389-403

f Division of Surgical Oncology , Rutgers Cancer Institute of New Jersey , New Brunswick , NJ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2015.1115725DOI Listing
July 2016

Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab.

Cancer Immunol Res 2016 07 13;4(7):569-73. Epub 2016 May 13.

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940026PMC
July 2016

Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy.

Cancer Immunol Res 2016 06 10;4(6):474-480. Epub 2016 Mar 10.

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891280PMC
June 2016

Pembrolizumab for the treatment of advanced melanoma.

Expert Opin Orphan Drugs 2016;4(8):867-873. Epub 2016 Jun 7.

Vanderbilt-Ingram Cancer Center; Vanderbilt University Medical Center, Division of Hematology-Oncology, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21678707.2016.1191348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010088PMC
June 2016

Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.

Immunotherapy 2015 22;7(6):611-9. Epub 2015 Jun 22.

Department of Surgery, Vanderbilt University Medical Center, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.15.35DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519012PMC
April 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.

Pigment Cell Melanoma Res 2016 Jan 20;29(1):101-3. Epub 2015 Aug 20.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12394DOI Listing
January 2016

Thyroid nodule: not as clear-cut as it seems.

J Community Support Oncol 2016 Jan;14(1):45-8

East Tennessee State University, Quillen College of Medicine, Medical Oncology and Hematology, Johnson City, Tennessee, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/jcso.0184DOI Listing
January 2016

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.

Br J Cancer 2015 Dec 22;113(11):1571-80. Epub 2015 Oct 22.

Cleveland Clinic Taussig Cancer Institute, Glickman Urological Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2015.368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705883PMC
December 2015

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.

Pigment Cell Melanoma Res 2015 Sep 23;28(5):611-2. Epub 2015 Jun 23.

Oncology Research and Development, Glaxo Smith Kline, Collegeville, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744965PMC
September 2015

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

J Clin Oncol 2015 Sep 26;33(25):2780-8. Epub 2015 May 26.

Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma Center, San Francisco; Gregory A. Daniels, University of California San Diego Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University Hospital and Health Network, Bethlehem, and Temple University School of Medicine, Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, Washington University School of Medicine, St Louis, MO; Kevin Harrington, Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, National Institute for Health Research Biomedical Research Centre, Oxford, United Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.

View Article

Download full-text PDF

Source
http://www.surgonc.org/docs/default-source/fellows-articles-
Web Search
http://jco.ascopubs.org/content/early/2015/06/16/JCO.2014.58
Web Search
http://jco.ascopubs.org/content/suppl/2015/05/26/JCO.2014.58
Web Search
http://dx.doi.org/10.1200/JCO.2014.58.3377DOI Listing
September 2015

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.

Anticancer Drugs 2015 Aug;26(7):785-92

aDivision of Hematology/Oncology, University of New Mexico Cancer Center, Albuquerque, New Mexico bDivision of Hematology-Oncology, Henry-Joyce Cancer Clinic/The Vanderbilt Clinic, Nashville, Tennessee cYale Cancer Center, Yale University, New Haven, Connecticut dFox Chase Cancer Center, Philadelphia, Pennsylvania eDepartment of Medicine, Division of Hematology-Oncology, University of Cincinnati Cancer Institute, Cincinnati, Ohio fSanofi, Bridgewater, New Jersey, USA gSanofi, Montpellier, France.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CAD.0000000000000250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484664PMC
August 2015

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

N Engl J Med 2015 Aug;373(8):726-36

From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut Bergonié Cancer Center, Bordeaux (A.I.) - all in France; University Hospital of Cologne, Cologne (J.W.), Universitätsmedizin Mannheim, Mannheim (R.-D.H.), West German Cancer Center, University Hospital Essen, Essen (M.S.), and German Cancer Consortium, Heidelberg (M.S.) - all in Germany; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona (M.E.E.-F., J.T.), and Hospital Universitario Madrid Sanchinarro, Madrid (M.H.) - both in Spain; and F. Hoffmann-La Roche, Basel, Switzerland (S.F.L., M.M., F.S., M.L.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1502309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971773PMC
August 2015

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

N Engl J Med 2015 Jul;373(5):428-37

From Memorial Sloan Kettering Cancer Center (W.D.T., J.H.H.) and Weill Cornell Medical College (W.D.T.) - both in New York; University of California, Los Angeles, Medical Center, Los Angeles (Z.A.W., B.C., A.S.S.), Plexxikon, Berkeley (P.N.I., C.Z., J.Z., G.H., Y.Z., E.A.B., G.V., L.S., P.S., H.N., M.J.K., A.M., G.T., R.S., C.G., B.L.W., P.H., K.N., H.H.H., P.S.L., S.T.-S., G.B.), and Stanford University School of Medicine, Stanford (M.R.) - all in California; Evergreen Hematology and Oncology, Spokane, WA (S.P.A.); University of Pennsylvania School of Medicine, Philadelphia (A.P.S.); Rocky Mountain Cancer Centers, Denver (A.L.C.); Dana-Farber Cancer Institute (G.I.S., A.J.W.) and Massachusetts General Hospital (E.L.K.) - both in Boston; Vanderbilt University Medical Center, Nashville (V.L.K., I.P.); Virginia G. Piper Cancer Center at Scottsdale Healthcare-Translational Genomics Research Institute (TGen), Scottsdale, AZ (D.D.V.H., G.J.W., R.K.R.); and Spire Sciences, Boca Raton, FL (C.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411366DOI Listing
July 2015

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

J Clin Oncol 2015 Jun 30;33(18):2013-20. Epub 2015 Mar 30.

David F. McDermott, Beth Israel Deaconess Medical Center; Toni K. Choueiri, Dana-Farber Cancer Institute/Brigham and Women's Hospital; Igor Puzanov and F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Charles G. Drake, Julie R. Brahmer, Hans J. Hammers, Suzanne L. Topalian, and Drew M. Pardoll, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Jon M. Wigginton, Georgia D. Kollia, Ashok Gupta, Dan McDonald, and Vindira Sankar, Bristol-Myers Squibb, Princeton, NJ; Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Nashville, TN; and Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517051PMC
June 2015

LK or IGF1R: When selectivity hurts.

Aging (Albany NY) 2015 Jun;7(6):342-3

Science Writer, Atlanta, Georgia, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505153PMC
http://dx.doi.org/10.18632/aging.100753DOI Listing
June 2015

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.

Cancer Immunol Res 2015 May 3;3(5):464-9. Epub 2015 Feb 3.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420706PMC
May 2015

Treatment of NRAS-mutant melanoma.

Curr Treat Options Oncol 2015 Apr;16(4):15

Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 777 Preston Research Building, 2220 Pierce Avenue, Nashville, TN, 37232, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-015-0330-z
Publisher Site
http://dx.doi.org/10.1007/s11864-015-0330-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830486PMC
April 2015

Management of 'pan-negative' melanoma: current and emerging strategies.

Melanoma Manag 2014 Nov 4;1(2):87-90. Epub 2014 Dec 4.

Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.14.21DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094662PMC
November 2014

A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

J Immunother 2013 Nov-Dec;36(9):490-5

*Dartmouth Hitchcock Medical Center, Lebanon, NH †Dana-Farber Cancer Institute, Harvard School of Public Health ∥Beth Israel Deaconess Medical Center ‡‡Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA ‡Vanderbilt University Medical Center, Nashville, TN §Loyola University Medical Center, Maywood, IL ¶Georgetown Lombardi Comprehensive Cancer Center, Washington, DC #St. Luke's Roosevelt Hospital Center, New York, NY **Earle A. Chiles Research Institute ††Providence Cancer Center, Portland, OR §§Department of Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI ∥∥Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CJI.0000000000000003DOI Listing
June 2014

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

J Clin Oncol 2014 Apr 3;32(10):1020-30. Epub 2014 Mar 3.

Suzanne L. Topalian, William H. Sharfman, Julie R. Brahmer, Evan J. Lipson, Janis M. Taube, and Drew M. Pardoll, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Mario Sznol and Harriet M. Kluger, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; David F. McDermott, Beth Israel Deaconess Medical Center; Donald P. Lawrence, Massachusetts General Hospital Cancer Center; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; Philip D. Leming, The Christ Hospital Cancer Center, Cincinnati, OH; Igor Puzanov and Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; David C. Smith, University of Michigan, Ann Arbor, MI; and Jon M. Wigginton, Georgia D. Kollia, and Ashok Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.0105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811023PMC
April 2014

Infectious Colitis Associated With Ipilimumab Therapy.

Gastroenterology Res 2014 Feb 14;7(1):28-31. Epub 2014 Mar 14.

Vanderbilt University Hospital, Division of Gastroenterology, Hepatology, and Nutrition, 1301 Medical Center Drive, 1160 The Vanderbilt Clinic, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14740/gr594eDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051139PMC
February 2014

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Clin Cancer Res 2013 Dec;19(24):6696-702

Authors' Affiliations: Departments of Cancer Biology, Biochemistry, Vanderbilt-Ingram Cancer Center; Departments of Pathology, Microbiology, and Immunology, Medicine, Division of Hematology-Oncology, Vanderbilt University School of Medicine; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee; Foundation Medicine, Inc., Cambridge, Massachusetts; and Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-1746DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880773PMC
December 2013

Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.

Future Oncol 2012 May;8(5):509-23

Vanderbilt-Ingram Cancer Center, Division of Hematology-Oncology, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232-6307, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon.12.31
Publisher Site
http://dx.doi.org/10.2217/fon.12.31DOI Listing
May 2012